CIK 0001894525 · <br>Emerging growth company
Apimeds Pharmaceuticals US, Inc.
Sign in to watch- Ticker
- APUS
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851099700
- Phone
- 848-201-5010
- Business address
- 100 MATAWAN RD, SUITE 325, MATAWAN, NJ, 07747
- 8-K Event Executive or director change
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chairman and CMO acquired 250,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 750,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Material agreement
- 10-Q Report Quarterly Report
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Open-market buy Chairman and CMO bought 27,500 shares at an average $1.83 ($50,359)
- NT 10-Q Other NT 10-Q
- 4 Open-market buy Director bought 28,500 shares at $1.99 ($56,715)
- 4 Open-market buy 10% owner bought 500,000 shares at $4.00 ($2,000,000)
- 3/A Insider 3/A
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- 424B4 Offering Prospectus
- 3 Insider Initial Statement of Ownership
Page 4 of 7 · 130 filings